Bristol Myers Squibb (BMY) Gross Margin (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Gross Margin for 18 consecutive years, with 71.28% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Gross Margin fell 124.0% year-over-year to 71.28% in Q2 2026; TTM through Jun 2026 was 70.16%, a 13.0% decrease from a year earlier, with the FY2025 full-year figure at 71.08%, changed 0.0% from the prior year.
• Gross Margin was 71.28% for Q2 2026 at Bristol Myers Squibb, up from 70.22% in the prior quarter.
• Over five years, Gross Margin peaked at 79.02% in Q3 2022 and troughed at 61.01% in Q4 2024.
• A 5-year average of 73.77% and a median of 74.76% in 2023 frame the typical range for Gross Margin.
• Across the five-year window, Gross Margin sank 1507 bps in 2024 and jumped 622 bps in 2025, its largest moves.
• Over 5 years, Gross Margin stood at 77.27% in 2022, then decreased by 2 bps to 76.08% in 2023, then fell by 20 bps to 61.01% in 2024, then gained by 10 bps to 67.23% in 2025, then advanced by 6 bps to 71.28% in 2026.
• The last three Gross Margin figures came in at 71.28% (Q2 2026), 70.22% (Q1 2026), and 67.23% (Q4 2025), per Business Quant data.